XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue $ 4,617,541 $ 4,235,344
Cost of goods sold 4,492,485 3,964,242
Gross Profit 125,056 271,102
Operating Expenses:    
Selling expenses 718,016 517,579
General and administrative expenses 1,362,246 1,544,731
Research and development expenses 230,123 254,812
Total Operating Expenses 2,310,385 2,317,122
Loss from Operations (2,185,329) (2,046,020)
Other Income (Expense):    
Interest and other income 68,751 69,086
Interest expense (48,283) (71,719)
Amortization of debt discount (168,030) (146,040)
Gain (loss) on foreign currency transactions 35,516 255,536
Gain (loss) on disposal of property and equipment (61,306) (463,577)
Total Other Expense (173,352) (356,714)
Loss Before Income Taxes (2,358,681) (2,402,734)
Income tax benefit (339) (14,439)
Net Loss (2,358,342) (2,388,295)
Net Loss attributable to noncontrolling interest (6,950) 0
Net Loss attributable to LiqTech International, Inc. $ (2,351,392) $ (2,388,295)
Loss Per Common Share – Basic and Diluted (in dollars per share) $ (0.25) $ (0.41)
Weighted-Average Common Shares Outstanding – Basic and Diluted (in shares) 9,602,354 5,804,702